Gladius Pharmaceuticals nets $4.1 mln in Series A led by Lumira Capital
Gladius Pharmaceuticals Inc has secured $4.1 million in a Series A financing. The round was led by Canadian venture capital firm Lumira Capital through its Merck Lumira Biosciences Funds. Joining Lumira in the deal was the Fonds de solidarité FTQ and SR One, an affiliate of GlaxoSmithKline. Based in Montréal, Gladius is a biotechnology company focused on developing novel drugs to treat life-threatening, multi-drug-resistant bacterial infections. It is led by CEO Michael Atkin. Lumira's Daniel Hétu said the Gladius technology "is demonstrating strong promise to restore treatment options for resistant Gram-negative infections which have become a global challenge."
22 June 2015•4 mins read
